Tumor-infiltrating lymphocytes (National Cancer Institute)

肿瘤浸润淋巴细胞（美国国立癌症研究所）

Report date: 2022/02/23 14:42:25

Base Information

Drug NameTumor-infiltrating lymphocytes (National Cancer Institute)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes

Mechanisms of ActionLymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsMelanoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Clinical)

Highest Status in ChinaN/A

Originator CompaniesNational Cancer Institute

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesNational Cancer Institute

Active IndicationsN/A

Inactive IndicationsMelanoma

Other Information

ATC CodeN/A